The FDA today approved Biogen and Alkermes’ diroximel fumarate, an oral agent, to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, ...

Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

Please provide your email address to receive an email when new articles are posted on . Cycle Pharmaceuticals announced that the FDA has approved its Tascenso ODT, a bioequivalent to Gilenya, or ...

An experimental stem cell therapy proved effective and safe in patients with a relapsing form of multiple sclerosis (MS), an autoimmune disease that affects the central nervous system, new research ...

Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.

Autologous haematopoietic stem cell transplantation, or aHSCT for short, is usually used to treat blood cancers, and involves harvesting stem cells from the person’s own bone marrow or blood followed ...

"Our findings prompt the inevitable question of whether the current phenotype classification of relapse-onset MS into relapsing-remitting and secondary progressive MS is as useful as we thought, for ...

This publication was sponsored and written in partnership with Bristol-Myers Squibb. The American Journal of Managed Care ®: What are some specific patient characteristics associated with ...